AALL0932 : Treatment of Patients With Newly Diagnosed Standard Risk B-Precursor Acute Lymphoblastic Leukemia (ALL) (Other ID's: CDR0000683227, COG-AALL0932)

Male or<br/>FemaleGender Male or
Female

RecruitingStatus Recruiting

Systemic<br/>Therapy TrialTypeSystemic
Therapy Trial

ThreePhase Three

1-9Age 1-9

Blood<br/>CancersCancer LocationBlood
Cancers

Systemic therapy | Blood / Myeloma / LymphomaAcute Lymphoblastic Leukaemia,Acute Lymphoblastic Lymphoma,B-Cell Non Hodgkin Lymphoma

Trial Overview Read MoreRead more

This phase III trial is evaluating different combinations of chemotherapy for the treatment of children who have Lymphoblastic Leukaemia or Lymphoblastic Lymphoma.
 

This trial is treating patients with Acute Lymphoblastic Leukaemia or Acute Lymphoblastic Lymphoma.

This is a systemic therapy trial.

You may be able to join this trial if:

  • You have been diagnosed with cancer, but have not received any treatment.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have been diagnosed with a prior or secondary type of cancer.
  • You have had certain treatments, surgical procedures or drugs.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

Treatment of Patients With Newly Diagnosed Standard Risk B-Precursor Acute Lymphoblastic Leukemia (ALL) (Other ID's: CDR0000683227, COG-AALL0932)

Cooperative Group

Children's Oncology Group

Other Non-Commercial Sponsor

National Cancer Institute (NCI)

Summary

RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy), giving the drugs in different doses, and giving the drugs in different combinations may kill more cancer cells. PURPOSE: This partially randomized phase III clinical trial is studying different combinations of risk-adapted chemotherapy regimens and their side effects and comparing how well they work in treating younger patients with newly diagnosed standard-risk acute lymphoblastic leukemia.

Recruiting Hospitals Read MoreRead more

Royal Childrens Hospital
Parkville
Ms Kahlia Fox
kahlia.fox@mcri.edu.au
(03) 9345 6214

Not Recruiting Hospitals Read MoreRead more

Closed

Monash Children's Cancer Centre
Clayton
Ms Irina Arzhintar
Irina.Arzhintar@monashhealth.org
(03) 8572 3490

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next